| Bioactivity | PHI-101 is an orally active FLT3 inhibitor that overcomes resistance to multiple drug-resistant mutations. PHI-101 potently inhibits FLT3 single activating mutations (ITD or TKD mutants) and has inhibitory activity against FLT3 double (ITD/D835Y or ITD/F691L) and triple (ITD/D835Y/F691L) resistance mutations. PHI-101 has potential for research in relapsed or refractory acute myeloid leukemia (AML)[1]. | ||||||||||||
| Name | PHI-101 | ||||||||||||
| CAS | 2127107-15-5 | ||||||||||||
| Formula | C19H19FN4O2S | ||||||||||||
| Molar Mass | 386.44 | ||||||||||||
| Appearance | 固体 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Nam K Y, et al. PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia[J]. Blood, 2020, 136: 28. |
PHI-101
CAS: 2127107-15-5 F: C19H19FN4O2S W: 386.44
PHI-101 is an orally active FLT3 inhibitor that overcomes resistance to multiple drug-resistant mutations. PHI-101 poten
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.